Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 6Unknown 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Carcinoma, Basal Cell 3Barrett Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Inflammatory Bowel Diseases 2Colonic Neoplasms 2Breast Neoplasms, Male 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tuberculosis 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Squamous Intraepithelial Lesions 1Small Cell Lung Carcinoma 1

Interventions

Fluorouracil 3Cyclophosphamide 3pegfilgrastim 2Paclitaxel 2Immunoenzyme Techniques 2Epirubicin 2Chemotherapy, Adjuvant 2Biopsy 2Bevacizumab 2Amplified Fragment Length Polymorphism Analysis 2orantinib 1eribulin 1Zoledronic Acid 1Therapeutics 1Taxes 1Sorafenib 1Radiotherapy 1Radioimmunodetection 1Pyridoxine 1Psychiatric Rehabilitation 1Neoadjuvant Therapy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunologic Techniques 1Ibandronic Acid 1Gene Rearrangement 1Gene Expression Profiling 1Flow Cytometry 1Drug Screening Assays, Antitumor 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms, Male × Biopsy × Clear all
NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Northwestern University

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02480933 2017-11-28

SISYPHUS

Centro Hospitalar Lisboa Ocidental

Phase NA Unknown
768 enrolled
Breast

Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡